TY - JOUR
T1 - Secondary prevention of stroke by blood pressure-lowering treatment
AU - Arima, Hisatomi
AU - Chalmers, John
PY - 2006/8
Y1 - 2006/8
N2 - High blood pressure is the most important modifiable risk factor for stroke, accounting for more than 50% of the population-attributable fraction for stroke. There is now strong evidence from randomized trials that blood pressure-lowering treatment is one of the most effective and generalizable strategies for secondary prevention of stroke. Once the patient with stroke has stabilized, all patients should receive blood pressure-lowering therapy, irrespective of their blood pressure levels. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor plus a diuretic is an established regimen, but an angiotensin II-receptor blocker may provide an alternative regimen in patients who do not tolerate an ACE inhibitor, especially in combination with a diuretic. For patients with previous stroke, goal blood pressures of < 130/80 mm Hg in hypertensive subjects and < 120/80 mm Hg in normotensive (or "prehypertensive") subjects should be achieved using combination blood pressure-lowering therapy.
AB - High blood pressure is the most important modifiable risk factor for stroke, accounting for more than 50% of the population-attributable fraction for stroke. There is now strong evidence from randomized trials that blood pressure-lowering treatment is one of the most effective and generalizable strategies for secondary prevention of stroke. Once the patient with stroke has stabilized, all patients should receive blood pressure-lowering therapy, irrespective of their blood pressure levels. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor plus a diuretic is an established regimen, but an angiotensin II-receptor blocker may provide an alternative regimen in patients who do not tolerate an ACE inhibitor, especially in combination with a diuretic. For patients with previous stroke, goal blood pressures of < 130/80 mm Hg in hypertensive subjects and < 120/80 mm Hg in normotensive (or "prehypertensive") subjects should be achieved using combination blood pressure-lowering therapy.
UR - http://www.scopus.com/inward/record.url?scp=33747620336&partnerID=8YFLogxK
U2 - 10.1007/s11906-006-0071-2
DO - 10.1007/s11906-006-0071-2
M3 - Review article
C2 - 16884663
AN - SCOPUS:33747620336
VL - 8
SP - 317
EP - 323
JO - CURRENT HYPERTENSION REPORTS
JF - CURRENT HYPERTENSION REPORTS
SN - 1522-6417
IS - 4
ER -